Drugs / AHB-137
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07600788 | May 2026 → May 2028 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05717686 | Feb 2023 → Jan 2025 | chronic hepatitis B virus infection | AusperBio Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06115993 | Aug 2023 → Dec 2024 | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07654283 | Sep 2026 → May 2027 expected | chronic hepatitis B virus infection | AusperBio Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07635186 | Jun 2026 → Jun 2027 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07370207 | Mar 2026 → Dec 2028 expected | chronic hepatitis B virus infection | AusperBio Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07137910 | Sep 2025 → Dec 2026 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06993480 | Jul 2025 → Jul 2026 overdue | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07069569 | Jun 2025 → Jul 2027 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06829329 | Dec 2024 → Aug 2026 overdue | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06550128 | Jul 2024 → May 2025 | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07246889 | Aug 2025 → Dec 2026 expected | chronic hepatitis B virus infection | Ausper Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-12-12 | Ausper Biopharma Co., Ltd. | Results AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy ausperbio.com ↗
The data demonstrated that finite-duration 24-week AHB-137 monotherapy achieved a 30% functional cure rate at Week 72 (EOF) in patients with baseline HBsAg 100–1,000 IU/mL. |
| 2025-11-08 | Ausper Biopharma Co., Ltd. | Results AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025 ausperbio.com ↗
Pooled 48-week results from two Phase II studies show sustained antiviral responses and a favorable safety profile of AHB-137 in HBeAg-negative chronic hepatitis B patients on NA therapy. |
| 2025-07-21 | Ausper Biopharma Co., Ltd. | Regulatory AusperBio Receives China CDE Clearance to Advance AHB-137 into Phase III Clinical Trial for Chronic Hepatitis B ausperbio.com ↗ |
| 2025-05-07 | Ausper Biopharma Co., Ltd. | Results AusperBio Presents Interim Phase IIb AHB-137 Clinical Data in a Late-Breaking Abstract at EASL™ Congress 2025 ausperbio.com ↗
The primary endpoint, HBsAg < 0.05 IU/mL, the lower limit of quantification (LLOQ), and HBV DNA < LLOQ (10 IU/mL) at the end of treatment, was achieved by 66% (21/32) in the 16-week arm and 75% (24/32) in the 24-week arm. |
| 2024-07-10 | Ausper Biopharma Co., Ltd. | Regulatory AusperBio Receives Breakthrough Therapy Designation for AHB-137 in Chronic Hepatitis B Treatment ausperbio.com ↗
AHB-137 gains Breakthrough Therapy Designation (BTD) from the NMPA based on Phase 1/Phase2a clinical trial data demonstrating safety and efficacy. |
| 2023-08-25 | Ausper Biopharma Co., Ltd. | Regulatory AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment ausperbio.com ↗
The FDA's clearance of our IND application to initiate clinical evaluation of AHB-137 in CHB patients in the United States brings us one step closer to introducing a potential functional cure for people living with HBV. |
| 2023-06-28 | Ausper Biopharma Co., Ltd. | Regulatory AusperBio Announces IND Approval from China CDE for HBV ASO AHB-137 ausperbio.com ↗
the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of AHB-137 to treat chronic hepatitis B (CHB) aiming for functional cure. |
All press releases naming this drug 19 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AHB-137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07069569 ↗ |
| Modality | Antisense oligonucleotide | “AHB-137 is a novel antisense oligonucleotide targeting a conserved 3'-terminal region of HBV mRNA.” PMID 42176239 ↗ May 2026 |
| Route | Subcutaneous | “by subcutaneous (SC) injection” NCT05717686 ↗ |